Imidazole antifungal
Miconazole
Inhibits fungal lanosterol 14α-demethylase, depleting ergosterol and disrupting membrane integrity.
Primary Mechanism of Action
Clinical / Scientific
Miconazole inhibits CYP51-dependent ergosterol synthesis. Membrane disorder and, at higher local concentrations, direct membrane-perturbing effects contribute to antifungal activity.
Pathway Targets
CYP51
Scientific explanation
Ergosterol biosynthesis blockade.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Fungal membrane failure
Target to downstream effect: CYP51 inhibition → Ergosterol depletion → Loss of membrane function
Mechanistically Relevant Repurposed & Adjunctive Applications
Susceptible fungal infections
EstablishedMechanistic rationale
Established imidazole for labelled mucosal and other susceptible mycoses depending on formulation.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| Fungal CYP51 | Inhibition | Ergosterol synthesis | Established mechanism |
Mechanistic Interaction Considerations
Systemic azoles can inhibit human CYPs; interaction relevance depends on exposure from the specific presentation.
In Plain Language
Miconazole blocks the fungal that makes ergosterol, weakening the fungus’s outer membrane.
Compounds Sharing Pathways
Other library compounds whose structured pathway data overlap this ingredient. Shared pathways are not combination recommendations.
CYP51
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.